A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma
This is a multicenter, open-label, dose-escalation study of MFGR1877S in patients with relapsed or refractory t(4;14)-positive multiple myeloma.
Multiple Myeloma
DRUG: MFGR1877S
Incidence and nature of dose-limiting toxicities (DLTs), Throughout study or until early study discontinuation
Incidence, nature, and severity of adverse events, Throughout study or until early study discontinuation|Clinical activity of MFGR1877S (objective response, duration of response, and progression-free survival), Throughout study or until early study discontinuation|Pharmacokinetic parameters of MFGR1877S (total exposure, maximum and minimum serum concentrations, clearance, volume of distribution), Throughout study or until early study discontinuation
This is a multicenter, open-label, dose-escalation study of MFGR1877S in patients with relapsed or refractory t(4;14)-positive multiple myeloma.